Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of JCAR014, Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor, in Combination With Durvalumab (MEDI4736) for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

NCT02706405 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT02706405
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02706405 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of JCAR014, Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor, in Combination With Durvalumab (MEDI4736) for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 1
Overall status
Terminated
Start date
November 15, 2016
Completion date
May 28, 2021
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma, not otherwise specified, recurrent diffuse large b-cell lymphoma, recurrent primary mediastinal (thymic) large b-cell lymphoma, refractory diffuse large b-cell lymphoma, refractory high grade b-cell lymphoma with myc, bcl2, and bcl6 rearrangements, refractory primary mediastinal (thymic) large b-cell lymphoma